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Accumulation of fibrillar amyloid -protein (A) in parenchymal plaques
and in blood vessels of the brain, the latter condition known as cerebral
amyloid angiopathy (CAA), are hallmark pathologies of Alzheimer’s disease
(AD) and related disorders. Cerebral amyloid deposits have been reported
to accumulate various metals, most notably copper and zinc. Here we show
that, in human AD, copper is preferentially accumulated in amyloidcontaining brain blood vessels compared to parenchymal amyloid plaques.
In light of this observation, we evaluated the effects of reducing copper
levels in Tg2576 mice, a transgenic model of AD amyloid pathologies. The
copper chelator, tetrathiomolybdate (TTM), was administered to twelve
months old Tg2576 mice for a period of five months. Copper chelation
treatment significantly reduced both CAA and parenchymal plaque load in
Tg2576 mice. Further, copper chelation reduced parenchymal plaque
copper content but had no effect on CAA copper levels in this model. These
findings indicate that copper is associated with both CAA deposits and
parenchymal amyloid plaques in humans, but less in Tg2576 mice. TTM only
reduces copper levels in plaques in Tg2576 mice. Reducing copper levels in
brain may beneficially lower amyloid pathologies associated with AD.
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Cerebral amyloid angiopathy (CAA) is a common cerebral small
vessel disease that involves the accumulation of amyloid protein (A) primarily in small- and medium-sized arteries and
arterioles of the meninges and cerebral cortex as well as along
the capillaries of the cerebral microvasculature1-4. CAA has been
shown to be present, in varying degrees, in nearly 80% of elderly
individuals5, 6. With the involvement of A, it is not surprising
that CAA is a very common vascular comorbidity in patients with
Alzheimer’s disease (AD)3, 4. Independent of AD, CAA is a
significant contributor to vascular-mediated cognitive
impairment and dementia (VCID)2, 7. CAA can uniquely
contribute to the cognitive decline in VCID and AD in several
ways. For example, the accumulation of amyloid in cerebral
blood vessels causes degeneration of cerebrovascular smooth
muscle cells and microvascular pericytes8-10. Also, CAA
promotes the increased expression and activation of certain
proteolytic enzymes in cerebral vascular cells 11-13. Together,
these processes can lead to loss of vessel wall integrity and
hemorrhage and/or chronic hypoperfusion and ischemic
infarcts2, 14-18. Yet, the reasons why cerebral vascular amyloid
develops and its contribution to downstream pathologies and
VCID remain unclear.
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Copper is an essential metal for normal brain development
and function as it is an important co-factor for a number of
enzymes and mitochondrial respiration 19-21. Altered brain
copper homeostasis has been considered to be a factor in the
pathogenesis of AD, but little is understood about the specific
mechanisms of action22. On one hand, there have been reports
of low plasma copper levels in AD 23, 24. Alternatively, other
studies have reported elevated levels of plasma copper in AD 25,
26. In particular, several studies have reported the accumulation
of copper ions in amyloid plaque deposits of AD patients and in
certain mouse models of parenchymal AD-like plaques27-30.
Further, several single nucleotide polymorphisms in the copper
transporter ATP7B gene are associated with a significant
increase in the risk for the development of AD 31-33. These
findings suggest that copper accumulation in parenchymal
amyloid plaques may be correlated with neurodegeneration
and cognitive impairment.
Mechanistically, this hypothesis is supported by in vitro
studies that demonstrated that copper binds to A, presumably
through three N-terminal histidine residues, resulting in a
reduction of Cu2+ to Cu+34. Copper-bound A has been shown to
be more prone to aggregation35 and also reacts with oxygen to
produce reactive oxygen species that can promote
neurodegeneration and thus cause cognitive impairment 36.
Specifically, copper-binding to Aβ has been shown to result in
hydroxyl radical formation and the production of hydrogen
peroxide, which activate a pro-inflammatory response in the
form of interleukin-1β and tumor necrosis factor-α, which
further contributes to neurodegeneration37{Kitazawa, 2016 #1435}.
Collectively, these studies suggest that copper may play an
important role in both the formation of amyloid plaques and in
subsequent neuronal dysfunction and cognitive impairment. In
contrast to previous work examining parenchymal amyloid
plaques, comparatively little is known about the accumulation
of copper in cerebral vascular amyloid deposits, which are
associated with VCID.
Here we report that CAA deposits contain higher copper
levels than parenchymal amyloid plaques in human AD brain.
We then hypothesized that copper plays a role in promoting
and/or stabilizing fibrillar amyloid deposition in CAA. Chronic
treatment of Tg2576 mice, a model of AD-like amyloid
pathologies, with the copper chelator TTM lowered the amount
of both cerebral vascular amyloid and parenchymal plaque
amyloid deposition. Further, TTM lowered the levels of copper
present only in parenchymal plaques and had no effect on CAA
copper levels. However, in Tg2576 mice, the copper level in
parenchymal plaques was modestly higher than in CAA
deposits, a finding distinct from human CAA. Nevertheless, the
present findings show that copper is strongly associated with
cerebral vascular amyloid and may play a role in amyloid
formation and subsequent CAA pathologies.

All work with animals was approved by the University of Rhode Island
and Stony Brook University Institutional Animal Care and Use
Committees and were conducted in conformity with the NIH Guide
for Care and Use of Laboratory Animals.
Tg2576 mice were obtained from Jackson Laboratories at
approximately three months of age and housed in a controlled room
(22 ± 2°C) with a 12h reverse light-dark cycle. At twelve months of
age cohorts of Tg2576 mice were administered drinking water
containing 5% sucrose (control) or 10mg/ml ammonium
tetrathiomolymbdate (TTM) (copper chelator) + 5% sucrose for a
period of five months. All administrations were prepared fresh and
replaced every third day. Weekly water consumption and monthly
body weights were determined for each animal in the study.
Brain tissue collection and preparation
Mice were euthanized at the end of the study and perfused with
cold-PBS, forebrains were removed and dissected through the midsagittal plane. One hemisphere was flash frozen in liquid nitrogen
and stored at -80 oC. For immunohistochemical studies, the other
hemisphere was immersion-fixed with 70% ethanol overnight and
subjected to increasing sequential dehydration in ethanol, followed
by xylene treatment and embedding in paraffin. Sagittal sections
were cut through the entire hemisphere at 10 µm thickness using a
Leica RM2135 microtome (Leica Microsystems Inc., Bannockburn,
IL), placed in a flotation water bath at 40°C, and then mounted on
Colorfrost/Plus slides (Fisher Scientific, Houston, TX).
X-ray fluorescence microscopy

Fresh frozen human AD brain tissue specimens containing both
parenchymal plaques and cerebral vascular amyloid were obtained
from the Neuropathology Core at University of California University
of California, Irvine.

For XFM studies, fresh frozen human AD brain tissue (n=3) and
Tg2576 mouse brain tissue (n=3 treated with TTM, n=3 untreated)
were sectioned at 20 µm and mounted on 4-µm-thick Ultralene film,
which was affixed to a 1.5” diameter Delrin ring. The localization of
amyloid was determined by staining the tissue sections with
thioflavin S. Prior to XFM data collection, the protein density in the
vessels was determined using Fourier transform infrared
microspectroscopy (FTIRM). Since the vessels can be denser than the
surrounding tissue, the protein density was used to normalize the
XFM data when quantifying the metal content, thus avoiding an
overestimate of the metal content within the vessels. FTIRM spectra
were acquired using a Spectrum Spotlight FTIR microscope with 8 cm1 spectral resolution over the mid-infrared spectral region (4000-800
cm-1). A 20 µm aperture was used with 64 scans per point. The
relative protein content at each pixel was determined by integrating
the Amide II protein peak from 1490 – 1580 cm-1 with a linear
baseline from 1480 – 1800 cm-1. The area under this peak is directly
proportional to the amount of protein in the specimen. The relative
protein density was calculated as the Amide II area on/off the
vessels.
The copper concentration within the vessels and plaques was
determined using synchrotron XFM at beamline 13-ID-E at the
Advanced Photon Source, Argonne National Laboratory and
beamlines 4-BM and 5-ID at the National Synchrotron Light Source II,
Brookhaven National Laboratory. The energy of the incident X-ray
beam was 10 keV. The X-ray beam was focused to a 1-3 µm spot size
using Kirkpatrick-Baez focusing mirrors. X-ray fluorescence was
detected by a Si-drift detector oriented at a 90° angle from the
incident beam. Energy dispersive spectra were collected at every
pixel.

Animal experiments

Quantitation of A peptides

Materials and Methods
Human AD brain tissues
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Total cerebral levels of Aβ40 and Aβ42 were determined by
performing specific ELISAs on mouse forebrain tissue homogenates
as described38, 39. In the sandwich ELISAs Aβ40 and Aβ42 were
captured using their respective carboxyl-terminal specific antibodies
mAb2G3 and mAb21F12 and biotinylated m3D6, specific for human
Aβ, was used for detection. Each mouse brain homogenate was
measured in triplicate and compared to linear standard curves
generated with known concentrations of human Aβ using a
Spectramax M2 plate reader (Molecular Devices, Sunnyvale, CA).
Immunohistochemical analysis
Antigen retrieval was performed by treating the tissue sections with
proteinase K (0.2 mg/ml) for 10 min at 22 °C. Primary rabbit
polyclonal antibody to collagen type IV was used to visualize cerebral
vessels (1:100; ThermoFisher, Rockford, IL). The primary antibody
was detected with Alexa Fluor 594-conjugated donkey anti-rabbit
secondary antibody (1:1000). Staining for fibrillar amyloid was
performed using thioflavin S. Brain tissue sections were imaged and
collected using an Olympus BX60 microscope with an attached
Olympus Dp72 camera. Images were collected from every tenth
section spanning the hemisphere.

Fig. 1. Higher copper content in cerebral vascular amyloid deposits compared
to parenchymal plaque amyloid deposits in the same AD brain tissue.
Epifluorescence images of the thioflavin S staining and corresponding copper
XFM images of parenchymal (A,C) and cerebral vascular (B,D) amyloid
deposits from the same AD brain tissue. Scale bars = 5 µm. (E) Relative copper
levels in the vascular amyloid deposits were ~3-fold higher than in
parenchymal amyloid plaques. Data shown are mean ± S.D. of n = 5 for each
type of amyloid deposit from the same tissues.

Quantitative analysis of amyloid pathologies

Administration of the copper chelator TTM to Tg2576 mice with ADlike amyloid pathologies

Using NIH ImageJ software, the percent area occupied with positive
stain was quantified. Percent area coverage of ThS+ parenchymal
plaques and ThS+ amyloid on blood vessels in the cortical regions was
determined.
Statistical Analysis
XFM, histological and immunochemical data were analyzed by t-test
at the 0.05 significance level.

Results
Cerebral vascular amyloid contains elevated copper levels
compared with parenchymal amyloid plaques in AD brain
Previous studies have reported that amyloid plaques in human AD
brain accumulate metal ions including iron, copper, and zinc 29, 30.
Here we sought to determine whether cerebral vascular amyloid
deposits similarly accumulate metal ions using the technique of x-ray
fluorescence microscopy (XFM). Fig. 1A and 1B show representative
thioflavin S stained images of fibrillar parenchymal amyloid plaques
and fibrillar cerebral vascular amyloid deposits, respectively. Fig. 1C
and 1D show the same deposits imaged for copper using XFM
demonstrating the elevated levels of copper in the CAA deposits.
Statistically, Fig. 1E shows that the copper content is ~3-fold higher
in vascular amyloid deposits when compared to plaques in human
AD brain tissue (p < 0.03). A similar trend was observed with the zinc
content, which showed that zinc was 2-3 times higher in the CAA
deposits compared to the amyloid plaques (data not shown).

To investigate if copper levels impact CAA and amyloid plaque
pathology in Tg2576 mice, we administered TTM through their
drinking water starting at twelve months of age, a point where both
cerebral vascular and parenchymal amyloid pathologies begin to
emerge in this model40, 41 Tg2576 mice were administered drinking
water containing either 5% sucrose + 10 mg/ml of the copper
chelator TTM or 5% sucrose alone for a period of five months. Weekly
water intake from each group of animals was not significantly
different (control = 214 ± 91 vs TTM = 171 ± 60; p = 0.2). Likewise,
both groups of Tg2576 mice started at similar weights (control = 32.2
± 5.1 vs TTM = 29.7 ± 6.1: p = 0.3) and finished the study at similar
weights (control = 39.1 ± 6.6 vs TTM = 33.5 ± 6.2; p = 0.06). Thus,
administration of TTM had no adverse effect on the general health
of the Tg2576 mice.
Copper chelation with TTM reduces cerebral vascular amyloid and
parenchymal plaque load in Tg2576 mice
Accumulation and deposition of A peptides in the brain is a key
pathological feature of AD that is replicated in Tg2576 transgenic
mice 40. Since we observed the presence of copper in cerebral
amyloid deposits in human AD brain (Fig. 1), we investigated the
effects of copper chelation on A accumulation in Tg2576 mice.
ELISA measurements for the total levels of forebrain A40 and A42
peptides revealed no significant difference between control and
TTM-treated Tg2576 mice (Fig. 2). Although copper chelation
treatment did not significantly affect the total cerebral accumulation
of A species we next evaluated the impact on compartmental
deposition of amyloid in the brains of the Tg2576 mice.

This journal is © The Royal Society of Chemistry 20xx
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Fig. 2. ELISA analysis of cerebral A40 and A42 peptides in control and TTMtreated Tg2576 mice. The total levels of A40 peptides (black bars) and A42
peptides (gray bars) in the forebrains of control and TTM-treated Tg2576 mice
were measured by ELISA as described under “Materials and Methods.” The
data presented are the means ± S.D. of triplicate measurements of n = 5-6
mice per group.

Fig. 3. TTM treatment reduces CAA load in Tg2576 mice. Brain sections from
control (A) and TTM-treated (B) Tg2576 mice were stained for fibrillar amyloid
using thioflavin-S (green) and immunolabeled for collagen type IV to identify
cerebral blood vessels (red). Scale bars = 50 µM. (C) Quantitation of cortical
vascular thioflavin-S positive amyloid load in control and TTM-treated Tg2576
mice. Data shown are mean ± S.D. of n = 5 Tg2576 mice per group.

Staining for fibrillar amyloid deposition using thioflavin S
revealed the presence of cortical CAA, mainly in the surface
meningeal vessels. Morphologically there was no discernible
difference between the appearance of CAA in the control and TTMtreated Tg2576 mice (Fig. 3A and 3B, respectively). However,
quantifying the amount of cortical CAA revealed a significant
reduction (p < 0.05) in the amount of vessel coverage with amyloid
in the TTM-treated Tg2576 mice (Fig. 3C). Similarly, staining for
fibrillar amyloid showed the presence of parenchymal plaques in
both control and TTM-treated Tg2576 mice (Fig. 4A and 4B,
respectively). Again, there was no apparent difference in the
morphology of the fibrillar amyloid plaques. Yet, similar to the
findings with CAA, there was a significant reduction (p < 0.05) in
percentage of cortical area occupied by fibrillar amyloid plaques (Fig.
4C). Together, these findings indicate that copper chelation with TTM
treatment reduced the amount of both fibrillar CAA and
parenchymal plaque amyloid deposition in Tg2576 mice.

Fig. 4. TTM treatment reduces cortical amyloid plaque load in Tg2576 mice.
Brain sections from control (A) and TTM-treated (B) Tg2576 mice were
stained for fibrillar amyloid using thioflavin-S (green) and immunolabeled for
collagen type IV to identify cerebral blood vessels (red). Scale bars = 50 µM.
(C) Quantitation of cortical thioflavin-S positive amyloid plaque load in control
and TTM-treated Tg2576 mice. Data shown are mean ± S.D. of n = 5 Tg2576
mice per group.

Copper chelation with TTM reduces copper content of parenchymal
amyloid plaques but not of CAA in Tg2576 mice
Since copper chelation treatment lowered both CAA and
parenchymal plaque load in the Tg2576 mice, we next determined if
this treatment also changed the copper content in these distinct
cerebral amyloid lesions. We performed XFM on CAA and
parenchymal amyloid plaque deposits in control and TTM-treated
Tg2576 mice that were identified by staining with thioflavin S (Fig. 5).

4 | J. Name., 2012, 00, 1-3
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Fig. 5. TTM treatment reduces cortical amyloid plaque copper levels in
Tg2576 mice. Brain sections from control and TTM-treated Tg2576 mice were
stained with thioflavin S to identify fibrillar amyloid deposits in cerebral
vessels (V) and parenchymal amyloid plaques (P). The relative copper levels
in these deposits were determined using XFM and tissue density was
normalized using FTIR microspectroscopy. All Cu images are shown on the
same intensity scale. Histograms shown are mean ± S.D. of n = 5 Tg2576 mice
per group.

Interestingly, we found that the copper content in parenchymal
amyloid plaques was significantly higher (p < 0.01) than the cerebral
vascular amyloid deposits in Tg2576 mice, which was the opposite of
what was observed in human AD brain tissue (Fig. 1). TTM treatment
significantly lowered (p < 0.01) the copper content of parenchymal
amyloid plaques but had no effect on reducing the copper content of
CAA deposits. At the end of TTM treatment, the copper content of
vascular and parenchymal amyloid deposits was essentially the
same. These findings indicate that although TTM treatment similarly
reduces CAA and parenchymal plaque load it only lowers copper
content in the parenchymal amyloid plaques in Tg2576 mice.

Discussion
CAA is a common cerebral small vessel disease of the elderly and a
prominent comorbidity of AD that promotes and exacerbates VCID,
yet our understanding of the condition remains limited. Both CAA
and AD are characterized by the accumulation of fibrillar Aβ in the
brain vessels and parenchyma, respectively. In human AD, metal ions
including iron, copper, and zinc have been shown to co-localize with
the parenchymal plaques 29, 30. But while the parenchymal plaques in
AD have been studied extensively, little is known about metal-ion
accumulation in amyloid-containing brain vessels in AD. Here we
examined the cerebral vascular amyloid in human AD and found that
the copper content was ~3-fold higher than the parenchymal plaques
and >10-fold higher than surrounding brain tissue. This finding
supports the hypothesis of an environment for toxic redox chemistry

in the vessel walls, leading to pro-inflammatory responses that may
play a role in the degeneration of cerebrovascular cells, which can
lead to loss of vessel wall integrity and subsequent CAA
pathologies37, 42.
In contrast to human AD, the PSAPP and 5XFAD mouse models of
AD show little or no metal accumulation in the parenchymal plaques
27, 28. Results presented here for the Tg2576 mouse model show
similar results. Given the similarly low copper levels in parenchymal
plaques from all mouse models, and the observations that mouse
models also show much less neuronal loss than humans, it has been
suggested that copper binding to Aβ plaques generates redoxinitiated toxic species that contribute to neurodegeneration.
Unlike previous work that focused only on parenchymal plaques,
this is the first study to examine both parenchymal plaques and
vascular amyloid in the same animals. Results show that, for the
Tg2576 mouse model, the copper-binding in both plaques and
vessels is considerably lower than what has been observed in
humans and, surprisingly, parenchymal plaques have a slightly higher
copper content than the vascular amyloid. Studies on vascular and
parenchymal amyloid have shown that the primary Aβ species in the
vasculature is Aβ40, whereas the parenchymal plaques contain
primarily Aβ42 3, 4. Further, recent studies have shown that in
vascular amyloid the fibrils possess an anti-parallel configuration that
is distinct from the parallel fibril orientation observed in
parenchymal plaques. Thus, we suggest that peptide length and/or
structural differences between vascular and parenchymal Aβ fibrils
may affect copper-binding.
Given the potential role of copper in CAA pathogenesis, we
assessed whether copper chelation treatment would alleviate the
amyloid burden in the brain vasculature and parenchyma of Tg2576
mice. We found that copper chelation treatment had no significant
effect on the levels of cerebral A40 or A42 (Fig. 2). It has been
shown that copper binds to the amyloid precursor protein (APP) 43
and causes a reduction of Cu(II) to Cu(I) 44. Further binding of copper
to APP can also modulate APP processing by γ-secretase and Aβ
peptide production 45, 46. However, our finding of no significant effect
of copper chelation on A peptide levels in Tg2576 mouse brain
suggests that this treatment is not appreciably impacting APP
processing and Aβ production.
Copper also binds to the Aβ peptide directly 47-51 where three
histidine residues control the redox activity of the copper ion 52.
Moreover, when bound to Aβ fibrils, copper redox chemistry can lead
to the formation of hydrogen peroxide and generation of reactive
oxygen species 37 and treatment with TTM has been shown to invoke
anti-inflammatory responses53. In contrast to the ELISA measures of
total cerebral A40 and A42 levels we show that the fibrillar
vascular Aβ deposits and plaque burdens were both significantly
reduced with copper chelation in the Tg2576 mice. This could suggest
that copper plays a role in the formation and/or stabilization of the
Aβ fibrils and, when copper is lowered, this results in reduced
amyloid burden.
Even though the amyloid burden is lowered in both the vessels
and plaques, the level of copper-binding in the amyloid that still
forms is similarly low with or without the copper chelator. The only
exception is the parenchymal plaques, which have a slightly higher
level of copper-binding that is lowered by TTM. It is possible that the
higher burden of parenchymal plaque amyloid compared to vascular
amyloid in the Tg2576 mice provides more of a reservoir to bind
copper in brain. Alternatively, since parenchymal plaques are
primarily composed of Aβ42 3, 4, this could suggest that, in Tg2576
mice, copper may preferentially bind Aβ42 fibrils compared to Aβ40
fibrils and, when copper is lowered, results in decreased copper

This journal is © The Royal Society of Chemistry 20xx
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binding in the parenchymal plaques. On the other hand, the inability
of TTM to lower copper content in vascular amyloid may reflect
stronger binding to these particular amyloid fibrils that were recently
shown to possess a distinct anti-parallel structure 41.
In summary, we find that copper binding to CAA vessels is
significantly higher than parenchymal plaques in human AD brain.
Toxic redox chemistry associated with this higher level of copper in
the vessels may contribute to degeneration of cerebral vascular cells
and subsequent loss of vessel wall integrity. In contrast, the Tg2576
mouse model of AD showed much lower levels of copper binding to
amyloid in both the brain vessels and parenchymal plaques.
Moreover, treatment with TTM had little effect on the copper
content in the vessels or plaques in this model. Interestingly,
however, TTM was shown to significantly reduce the amount of
fibrillar amyloid in both the CAA vessels and parenchymal plaques.
These findings suggest that chelation of copper in the Tg2576 mouse
model may affect amyloid fibril formation and/or stabilization.
However, in the CAA deposits and parenchymal plaques that still
form, the copper content is considerably lower than the human
condition, in agreement with earlier studies from other mouse
models of AD. Together, this supports the hypothesis that redox
chemistry associated with copper binding to Aβ results in the
production of toxic species that contribute to cellular degeneration
and these pathological processes are not robust in mouse models of
AD.
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